文献速递冠心病

ISCHEMIA试验:基于冠状动脉病变与缺血严重程度的结果分析

Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity.
PubMed 文献 · Circulation · 2021-09-09

ISCHEMIA试验纳入5179例中重度缺血患者,随机接受初始侵入或保守策略,分析冠脉病变(改良Duke预后指数,n=2475)与缺血严重程度(核心实验室判读,n=5105)和4年结局的关系。结果显示,校正冠脉病变后缺血严重程度与死亡风险无关,而冠脉病变越重死亡和心梗风险越高;侵入策略未降低任何缺血或病变亚组的4年全因死亡率。

要点

  • 缺血严重程度与死亡风险无关,但非致死性心梗风险随缺血加重呈趋势升高。
  • 冠脉病变越重,死亡和心梗风险越高;最重病变亚组侵入策略心血管死亡或心梗率较低。
  • 侵入策略未降低任何缺血或冠脉病变亚组的4年全因死亡率。

核心结论

  • 校正冠脉病变严重程度后,缺血严重程度与死亡风险增加无关。
  • 冠脉病变越严重,死亡和心梗风险越高。
  • 侵入管理未降低任何缺血或冠脉病变亚组的4年全因死亡率。

研究设计与样本

  • ISCHEMIA试验共随机5179例中重度缺血患者至初始侵入或保守策略。
  • 采用盲法核心实验室判读的冠脉CT血管造影评估解剖 eligibility。
  • 改良Duke预后指数分类冠脉病变(n=2475,48%),独立核心实验室判读缺血(n=5105,99%)。
  • 比较不同缺血和冠脉病变严重程度亚组的4年事件率,主要终点为全因死亡。

主要发现

  • 与轻度/无缺血相比,中度和重度缺血均未增加死亡风险(中度HR 0.89,95%CI 0.61-1.30;重度HR 0.83,95%CI 0.57-1.21;P=0.33)。
  • 非致死性心梗率随缺血严重程度加重而升高(中度HR 1.20,95%CI 0.86-1.69;重度HR 1.37,95%CI 0.98-1.91;趋势P=0.04,校正冠脉病变后P=NS)。
  • 冠脉病变最重亚组与最轻亚组相比,死亡HR 2.72(95%CI 1.06-6.98),心梗HR 3.78(95%CI 1.63-8.78)。
  • 缺血严重程度未识别出在死亡、心梗、试验主要终点或心血管死亡或心梗方面从治疗获益的亚组。
  • 最重冠脉病变亚组(n=659)中,侵入策略组4年心血管死亡或心梗率较低(差异6.3%,95%CI 0.2%-12.4%),但4年全因死亡率相似。

临床怎么用

  • 临床评估稳定性冠心病患者时,应重视冠脉病变解剖严重程度对死亡和心梗风险的预测价值。
  • 缺血严重程度在校正冠脉病变后未显示独立增加死亡风险,不宜单独据此决定侵入策略。
  • 侵入管理未降低任何缺血或冠脉病变亚组的4年全因死亡率,支持个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) postulated that patients with stable coronary artery disease (CAD) and moderate or severe ischemia would benefit from revascularization. We investigated the relationship between severity of CAD and ischemia and trial outcomes, overall and by management strategy. METHODS: In total, 5179 patients with moderate or severe ischemia were randomized to an initial invasive or conservative management strategy. Blinded, core laboratory-interpreted coronary computed tomographic angiography was used to assess anatomic eligibility for randomization. Extent and severity of CAD were classified with the modified Duke Prognostic Index (n=2475, 48%). Ischemia severity was interpreted by independent core laboratories (nuclear, echocardiography, magnetic resonance imaging, exercise tolerance testing, n=5105, 99%). We compared 4-year event rates across subgroups defined by severity of ischemia and CAD. The primary end point for this analysis was all-cause mortality. Secondary end points were myocardial infarction (MI), cardiovascular death or MI, and the trial primary end point (cardiovascular death, MI, or hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest). RESULTS: Relative to mild/no ischemia, neither moderate ischemia nor severe ischemia was associated with increased mortality (moderate ischemia hazard ratio [HR], 0.89 [95% CI, 0.61-1.30]; severe ischemia HR, 0.83 [95% CI, 0.57-1.21]; P=0.33). Nonfatal MI rates increased with worsening ischemia severity (HR for moderate ischemia, 1.20 [95% CI, 0.86-1.69] versus mild/no ischemia; HR for severe ischemia, 1.37 [95% CI, 0.98-1.91]; P=0.04 for trend, P=NS after adjustment for CAD). Increasing CAD severity was associated with death (HR, 2.72 [95% CI, 1.06-6.98]) and MI (HR, 3.78 [95% CI, 1.63-8.78]) for the most versus least severe CAD subgroup. Ischemia severity did not identify a subgroup with treatment benefit on mortality, MI, the trial primary end point, or cardiovascular death or MI. In the most severe CAD subgroup (n=659), the 4-year rate of cardiovascular death or MI was lower in the invasive strategy group (difference, 6.3% [95% CI, 0.2%-12.4%]), but 4-year all-cause mortality was similar. CONCLUSIONS: Ischemia severity was not associated with increased risk after adjustment for CAD severity. More severe CAD was associated with increased risk. Invasive management did not lower all-cause mortality at 4 years in any ischemia or CAD subgroup. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01471522.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Reynolds HR, Shaw LJ, Min JK, et al. Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. Circulation. 2021. PMID: 34496632. doi:10.1161/CIRCULATIONAHA.120.049755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。